VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy
Completed
Vion Pharmaceuticals
Phase 1
1999-08-01
RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune
system and stop cancer cells from growing.
PURPOSE: Phase I trial to study the effectiveness of VNP20009 in treating patients who have
advanced or metastatic solid tumors that have not responded to previous therapy.
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
Completed
National Cancer Institute (NCI)
Phase 1
2004-05-01
RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different
ways to stop tumor cells from dividing so they stop growing or die. Temozolomide may help
irinotecan kill more tumor cells by making them more sensitive to the drug. Cefixime may be
effective in preventing diarrhea that is caused by treatment with irinotecan.
PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when
given together with temozolomide and cefixime in treating young patients with recurrent or
resistant neuroblastoma.
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
Completed
Children's Hospital Los Angeles
Phase 1
2004-05-01
RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different
ways to stop tumor cells from dividing so they stop growing or die. Temozolomide may help
irinotecan kill more tumor cells by making them more sensitive to the drug. Cefixime may be
effective in preventing diarrhea that is caused by treatment with irinotecan.
PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when
given together with temozolomide and cefixime in treating young patients with recurrent or
resistant neuroblastoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
